For those that thought embryonic research is illegal in the U.S., this is an interesting article. It is the federal funding that is restricted, not the research.
In his Bull Market.com, he explains, "Geron (NASDAQ: GERN) is the current leader in embryonic stem cell research among publicly traded companies." Here's his review of the stock and the controversial research sector.
"Embryonic stem cell research in the U.S. is not restricted in any way, as is often popularly believed in this hotly contested debate.
"The real issue at hand is federal funding, and whether federal taxpayer dollars should be used to help fund the research.
"Currently, federal funding is only available to firms that won't create embryos for use in scientific research or clone them for any reason, and that are working with stem cell lines derived from embryos destroyed before August 9th, 2001.
"In addition, the stem cell lines must have been obtained from 'left over' embryos created solely for in-vitro fertilization purposes from consenting donors without any financial incentive.
"According to a September 2003 NIH report, only one publicly traded company of the more than a dozen institutions listed had stem cell lines that qualified for federal funding was Geron, which has been a pioneer in the field since 1999.
"Embryonic stem cell research is among three areas of concentration for the biotech firm, and it has a large number of related stem cell patents. Some of its major areas of focus include spinal cord injuries, heart disease, and diabetes.
In his Bull Market.com, he explains, "Geron (NASDAQ: GERN) is the current leader in embryonic stem cell research among publicly traded companies." Here's his review of the stock and the controversial research sector.
"Embryonic stem cell research in the U.S. is not restricted in any way, as is often popularly believed in this hotly contested debate.
"The real issue at hand is federal funding, and whether federal taxpayer dollars should be used to help fund the research.
"Currently, federal funding is only available to firms that won't create embryos for use in scientific research or clone them for any reason, and that are working with stem cell lines derived from embryos destroyed before August 9th, 2001.
"In addition, the stem cell lines must have been obtained from 'left over' embryos created solely for in-vitro fertilization purposes from consenting donors without any financial incentive.
"According to a September 2003 NIH report, only one publicly traded company of the more than a dozen institutions listed had stem cell lines that qualified for federal funding was Geron, which has been a pioneer in the field since 1999.
"Embryonic stem cell research is among three areas of concentration for the biotech firm, and it has a large number of related stem cell patents. Some of its major areas of focus include spinal cord injuries, heart disease, and diabetes.